Joan Oh, Puneet Chawla Sahota, Tarannum Mohammadi, Basant K Pradhan, Maju Mathew Koola
{"title":"COVID-19和紧张症:患病率、挑战、病理生理学和治疗。","authors":"Joan Oh, Puneet Chawla Sahota, Tarannum Mohammadi, Basant K Pradhan, Maju Mathew Koola","doi":"10.12788/acp.0109","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Emerging literature supports the association between acute COVID-19 infection and neuropsychiatric complications. This article reviews the evidence for catatonia as a potential neuropsychiatric sequela of COVID-19 infection.</p><p><strong>Methods: </strong>PubMed was searched using the terms catatonia, severe acute respiratory syndrome coronavirus 2, and COVID-19. Articles were limited to those published in the English language between 2020 and 2022. Forty-five articles that specifically studied catatonia associated with acute COVID-19 infection were screened.</p><p><strong>Results: </strong>Overall, 30% of patients with severe COVID-19 infection developed psychiatric symptoms. We found 41 cases of COVID-19 and catatonia, with clinical presentations that varied in onset, duration, and severity. One death was reported in a case of catatonia. Cases were reported in patients with and without a known psychiatric history. Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments.</p><p><strong>Conclusions: </strong>Greater recognition and treatment of catatonia in individuals with COVID-19 infection is warranted. Clinicians should be familiar with recognizing catatonia as a potential outcome of COVID-19 infection. Early detection and appropriate treatment are likely to lead to better outcomes.</p>","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"35 2","pages":"118-130"},"PeriodicalIF":1.5000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment.\",\"authors\":\"Joan Oh, Puneet Chawla Sahota, Tarannum Mohammadi, Basant K Pradhan, Maju Mathew Koola\",\"doi\":\"10.12788/acp.0109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Emerging literature supports the association between acute COVID-19 infection and neuropsychiatric complications. This article reviews the evidence for catatonia as a potential neuropsychiatric sequela of COVID-19 infection.</p><p><strong>Methods: </strong>PubMed was searched using the terms catatonia, severe acute respiratory syndrome coronavirus 2, and COVID-19. Articles were limited to those published in the English language between 2020 and 2022. Forty-five articles that specifically studied catatonia associated with acute COVID-19 infection were screened.</p><p><strong>Results: </strong>Overall, 30% of patients with severe COVID-19 infection developed psychiatric symptoms. We found 41 cases of COVID-19 and catatonia, with clinical presentations that varied in onset, duration, and severity. One death was reported in a case of catatonia. Cases were reported in patients with and without a known psychiatric history. Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments.</p><p><strong>Conclusions: </strong>Greater recognition and treatment of catatonia in individuals with COVID-19 infection is warranted. Clinicians should be familiar with recognizing catatonia as a potential outcome of COVID-19 infection. Early detection and appropriate treatment are likely to lead to better outcomes.</p>\",\"PeriodicalId\":50770,\"journal\":{\"name\":\"Annals of Clinical Psychiatry\",\"volume\":\"35 2\",\"pages\":\"118-130\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12788/acp.0109\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12788/acp.0109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment.
Background: Emerging literature supports the association between acute COVID-19 infection and neuropsychiatric complications. This article reviews the evidence for catatonia as a potential neuropsychiatric sequela of COVID-19 infection.
Methods: PubMed was searched using the terms catatonia, severe acute respiratory syndrome coronavirus 2, and COVID-19. Articles were limited to those published in the English language between 2020 and 2022. Forty-five articles that specifically studied catatonia associated with acute COVID-19 infection were screened.
Results: Overall, 30% of patients with severe COVID-19 infection developed psychiatric symptoms. We found 41 cases of COVID-19 and catatonia, with clinical presentations that varied in onset, duration, and severity. One death was reported in a case of catatonia. Cases were reported in patients with and without a known psychiatric history. Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments.
Conclusions: Greater recognition and treatment of catatonia in individuals with COVID-19 infection is warranted. Clinicians should be familiar with recognizing catatonia as a potential outcome of COVID-19 infection. Early detection and appropriate treatment are likely to lead to better outcomes.
期刊介绍：
The ANNALS publishes up-to-date information regarding the diagnosis and /or treatment of persons with mental disorders. Preferred manuscripts are those that report the results of controlled clinical trials, timely and thorough evidence-based reviews, letters to the editor, and case reports that present new appraisals of pertinent clinical topics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
